Clinical Trials Browser

Completed × Interventional × Ipilimumab × Clear all

NCT04817254 2026-04-17

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Phase 2 Completed

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT03158129 2026-04-06

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

Phase 2 Completed

101 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT03459222 2026-04-06

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Phase 1/2 Completed

229 enrolled 21 charts

Advanced Cancer

NCT05704933 2026-04-06

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

Phase EARLY_PHASE1 Completed

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Phase 2 Completed

378 enrolled 15 charts 2 FDA

Uveal Melanoma, Melanoma

NCT05665348 2026-03-09

TRIPLET

Phase 2/3 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT04396860 2026-03-05

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Phase 2/3 Completed

159 enrolled 17 charts

Gliosarcoma

NCT07436390 2026-03-02

MAK

Phase NA Completed

Melanoma, Skin Neoplasms

NCT04290546 2026-02-27

CIML NK Cell in Head & Neck Cancer

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT03400332 2026-02-24

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Phase 1/2 Completed

281 enrolled 44 charts

Melanoma, Neoplasms

NCT03143153 2026-02-17

CheckMate 648

Phase 3 Completed

970 enrolled 15 charts 2 FDA

Various Advanced Cancer

NCT03600155 2026-02-17

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04362839 2026-01-28

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

Phase 1 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05136677 2026-01-23

CheckMate 6DW

Phase 2 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT04334759 2026-01-22

DREAM3R

Phase 3 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT03285321 2026-01-20

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

105 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT03575793 2026-01-20

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Phase 1/2 Completed

39 enrolled 18 charts

Lung Neoplasms

NCT03873818 2026-01-09

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

Phase 2 Completed

24 enrolled 13 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04326257 2026-01-08

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Phase 2 Completed

20 enrolled 13 charts

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT02998528 2026-01-06

CheckMate 816

Phase 3 Completed

505 enrolled 17 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04717154 2026-01-06

INSPIRE

Phase 2 Completed

Prostatic Neoplasms, Castration-Resistant

NCT01658878 2025-12-24

CheckMate040

Phase 1/2 Completed

657 enrolled 57 charts 5 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT02985957 2025-12-22

CheckMate 650

Phase 2 Completed

351 enrolled 43 charts

Prostatic Neoplasms

NCT01701674 2025-12-19

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Phase NA Completed

13 enrolled 10 charts

Melanoma, Skin Neoplasms

NCT03172624 2025-12-18

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Phase 2 Completed

64 enrolled 9 charts

Salivary Gland Neoplasms

NCT03388632 2025-12-18

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Phase 1 Completed

31 enrolled 20 charts

Other solid neoplasm

Metastatic Solid Tumors

NCT03215706 2025-12-17

CheckMate 9LA

Phase 3 Completed

719 enrolled 21 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT03245892 2025-12-17

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

Phase 1 Completed

High Grade Serous Ovarian

NCT01950390 2025-12-11

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Phase 2 Completed

169 enrolled 14 charts

Melanoma

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT03377361 2025-12-03

CheckMate 9N9

Phase 1/2 Completed

325 enrolled 31 charts

Gastrointestinal

Colorectal Neoplasms

NCT04021043 2025-12-03

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers

Phase 1/2 Completed

51 enrolled 16 charts

Neoplasm Metastasis

NCT03369223 2025-11-18

A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Phase 1/2 Completed

356 enrolled 43 charts

Advanced Cancer

NCT03469960 2025-11-18

DICIPLE

Phase 3 Completed

Non-Small Cell Lung Cancer Metastatic

NCT02939300 2025-11-14

Ipilimumab and Nivolumab in Leptomeningeal Metastases

Phase 2 Completed

18 enrolled 17 charts

Meningeal Carcinomatosis

NCT02060188 2025-11-06

CheckMate142

Phase 2 Completed

385 enrolled 17 charts 4 FDA

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT02477826 2025-10-30

CheckMate 227

Phase 3 Completed

2,747 enrolled 21 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Phase 1/2 Completed

320 enrolled 35 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT03573947 2025-10-14

TOP1705

Phase 2 Completed

46 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT03404960 2025-10-10

Parpvax

Phase 1/2 Completed

104 enrolled 11 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT04887870 2025-10-10

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Phase 2/3 Completed

Advanced or Metastatic Solid Malignancies

NCT04465643 2025-10-08

Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor

Phase 1 Completed

Nerve Sheath Neoplasms

NCT05407675 2025-10-03

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

68 enrolled 27 charts

Neoplasms

NCT03949153 2025-10-01

CRIRIN

Phase 1/2 Completed

Melanoma

NCT03075423 2025-09-26

Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

Phase 2 Completed

Carcinoma, Renal Cell

NCT04850755 2025-09-25

A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies

Phase 1 Completed

Advance Solid Malignancies

NCT03195478 2025-09-15

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

Phase 1/2 Completed

37 enrolled 32 charts

Other solid neoplasm

Solid Tumor

NCT02498600 2025-08-29

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

100 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04988841 2025-08-28

PICASSO

Phase 2 Completed

Melanoma

NCT05004025 2025-08-15

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

Phase 1 Completed

Uveal Melanoma